Tandem Diabetes Care, Inc. TNDM

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
49/100
Developing

Ranked against 159 peers in Medical Devices

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the … Full TNDM analysis →

Key strengths

  • Stable Gross Margin Profile Gross margin stability is strong (score 0.74). Low volatility confirms durable consumable pricing.

Key risks

  • Weak Capital Return Profile Capital return quality is below peers (score 0.36). Low ROIC raises questions about M&A discipline and pipeline ROI.
  • Thin Interest Coverage Interest coverage lags peers (score 0.24). Thin coverage limits M&A optionality and raises refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
56
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Where TNDM ranks in Medical Devices

Tandem Diabetes Care, Inc. ranks #81 of 160 scored companies in Medical Devices by moat score — the top 51%. The widest moat in the group is iRadimed Corporation (IRMD) at 83/100.

# Company Moat score Rating
77 CVRx, Inc. CVRX 49/100 Developing
78 Profound Medical Corp. PROF 49/100 Developing
79 Butterfly Network, Inc. BFLY 49/100 Developing
80 Accuray Incorporated ARAY 49/100 Developing
81 Tandem Diabetes Care, Inc. TNDM 49/100 Developing
82 DIH Holding US, Inc. DHAI 48/100 Developing
83 Baird Medical Investment Holdings Limited BDMDW 48/100 Developing
84 Baird Medical Investment Holdin BDMD 48/100 Developing
85 NeuroOne Medical Technologies C NMTC 48/100 Developing

See every Medical Devices & Diagnostics company ranked by moat score →

How TNDM scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Score 56 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Score 44 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Score 54 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Score 60 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Score 17 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Score 49 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding TNDM's moat

What is Tandem Diabetes Care, Inc.'s moat score?

Tandem Diabetes Care, Inc. (TNDM) scores 48 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #81 of 160 scored companies in Medical Devices, the top 51%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 159 companies in Medical Devices. Its strongest defense is Commercial Execution (60/100) and its weakest is Capital Structure & Resilience (17/100).

How does Tandem Diabetes Care, Inc. compare with other Medical Devices companies?

Tandem Diabetes Care, Inc. ranks #81 of 160 scored companies in Medical Devices by moat score. The widest moat in Medical Devices is iRadimed Corporation (IRMD) at 83/100. The companies ranked closest are Accuray Incorporated (ARAY) at 49 just above it and DIH Holding US, Inc. (DHAI) at 48 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 159 companies in Medical Devices. The defenses are then weighted to produce the overall score out of 100.

Why is Tandem Diabetes Care, Inc. scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for Tandem Diabetes Care, Inc.?

The Medical Devices & Diagnostics template measures 6 defenses, and TNDM scores: Pricing Power & Consumable Moat (56), R&D Pipeline & Capital Returns (44), FCF Quality & Cash Conversion (54), Commercial Execution (60), Capital Structure & Resilience (17), Growth Durability (49). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000